This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation.
Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare. The Centers for Medicare & Medicaid Services (CMS), the federal agency that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results